Core-007

分子基因组学核心提供对遗传和表观遗传变异的高通量分析 南加州大学诺里斯分校的研究人员和临床医生。核心网站有两个发展良好的差异化网站：健康 科学校园(HSC)和洛杉矶儿童医院(CHLA)。HSC网站与研究一起工作 示例，而CHLA站点专门在符合CLIA的环境中提供服务。该设施是 由David Van Den Berg博士领导，他自1999年以来一直担任核心总监，并得到两个联合- 董事：Timothy Triche博士，自1999年以来，CHLA；Charles Nicolet博士，HSC，自2011年以来。《核心》 继续为癌症中心成员提供高通量的生物显微镜处理、DNA图谱分析 DNA甲基化和染色质构象的遗传变异、表观遗传学特征及其表达 侧写。 在上一次CCSG更新时，分子基因组核心获得了优秀到 太棒了。在项目期间，核心获得了更多的硬件平台(NanoString 计数器、Taqman低密度阵列、Ion Torrent PGM和质子、Fluidigm BioMark、2 x Illumina MiSeq 和2个Illumina NextSeq500)，以补充现有的遗传变异分析能力，表观遗传学 变异和基因表达。它是癌症甲基化检测的唯一数据生产站点 基因组图谱(TCGA)，为数不多的几个处理人类癌阵列珠芯片的站点之一 和最大的单核苷酸多态(SNP)和DNA甲基化阵列之一 在美国的生产基地。该机构还支持NCI儿童肿瘤学小组(COG)和NCI 资助的目标计划，该计划正在描绘儿童癌症类似于TCGA在成人癌症中的作用。 2013-2014财年，101名癌症中心成员(48%的用户)，其中80名由同行评议资助(38% 来自七个研究项目的用户)使用分子基因组学核心来完成他们的研究 目标。核心将继续利用在高吞吐量平台方面的专业知识，以提供经济高效的 从单碱基到全基因组分析的选择。核心将继续确定新技术和 为推进南加州大学诺里斯分校的研究并评估现有服务的成本效益而提供的服务 和附加值。

The Molecular Genomics Core provides high-throughput analysis of genetic and epigenetic variations to researchers and clinicians of the USC Norris. The Core has two well-developed and differentiated sites: Health Sciences Campus (HSC) and Children’s Hospital Los Angeles (CHLA). The HSC site works with research samples, while the CHLA site specializes in providing services in a CLIA-compliant environment. The facility is led by Dr. David Van Den Berg, who has served as Core Director since 1999, with the support of two Co- Directors: Dr. Timothy Triche, CHLA, since 1999, and Dr. Charles Nicolet, HSC, since 2011. The Core continues to provide Cancer Center members with high-throughput biospecimen processing, DNA profiling of genetic variation, epigenetic profiling of DNA methylation and chromatin conformation, and expression profiling. At the time of the last CCSG renewal, the Molecular Genomics Core received a merit rating of excellent to outstanding. During the project period, the Core has acquired additional hardware platforms (Nanostring nCounter, Taqman Low Density Arrays, Ion Torrent PGM and Protons, Fluidigm BioMark, 2 x Illumina MiSeq and 2 x Illumina NextSeq500) to supplement existing capabilities for analysis of genetic variation, epigenetic variation and gene expression. It served as the only data production site for methylation assays for The Cancer Genome Atlas (TCGA), one of only a few sites processing the HumanOncoArray beadchip the OncoChip Consortium, and one of the largest Illumina single nucleotide polymorphism (SNP) and DNA methylation array production sites in the US. The facility has also supported the NCI Children’s Oncology Group (COG) and NCI funded TARGET program, which is profiling childhood cancer akin to TCGA’s role in adult cancer. In FY 2013-2014, 101 Cancer Center members (48% of users), of which 80 were peer-reviewed funded (38% of users) from seven Research Programs used the Molecular Genomics Core to accomplish their research objectives. The Core will continue to utilize expertise in high-throughput platforms to provide cost-effective options from single base to genome-wide analysis. The Core will continue to identify new technologies and services that may be offered to advance USC Norris research and to evaluate existing services for costeffectiveness and value added.